Nucleocapsid Antibody (1051436) [Alexa Fluor™ Plus 488]

• Reactivity: V
• Clone: 1051436
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 488

Nucleocapsid Antibody (1051436) [Alexa Fluor™ Plus 488] Summary

• Specificity: Detects HCoV-OC43 Nucleocapsid in direct ELISA.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Nucleocapsid Antibody (1051436) [Alexa Fluor™ Plus 488]

• N Protein
• Nucleocapsid protein
• Nucleocapsid
• ORF9a protein

Background

HCoV-OC43, a virus first isolated in 1960's that accounts for ~ 20% of the common cold, belongs to a family of viruses known as coronaviruses that are commonly comprised of a large plus-strand RNA genome and four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1, 2). Other well-known human coronaviruses include three viruses that cause relatively mild respiratory disease: HCoV-229E, HCoV-HKU1 and HCov-NL63, plus three viruses that cause the Severe Acute Respiratory Syndrome (SARS-CoV), the Middle East Respirator Syndrome (MERS-CoV), and the global pandemic Covid-19 (SARS-CoV2). While the S, E and M proteins build up the viral envelop, the N protein is involved transcription, replication, and packaging of the viral RNA genome into a helical ribonucleocapsid (RNP) (3, 4). The CoV-OC43 N protein is a ~50 kDa protein composed of two independent structural domains connected by a linker region. Both the N-terminal and the linker regions contain RNA binding domains, while the C-terminal region is responsible for the oligomerization of the N protein (5). The CoV‑OC43 N protein shares 64% amino acid sequence identity with CoV-HKU1 N protein. the N protein is an abundant protein during coronavirus infection and displays high immunogenic activity. Cross activity of antibodies among different strains should be rigorously tested when designing serological diagnostic kits (6, 7).

1. St-Jean, J.R. et al. (2004) J. Virol. 78:8824.
2. Vabret, A. et al. (2003) Fr Clin Infect Dis. 36:985.
3. Chang, C.K. et al. (2006) J. Biomed. Sci. 13:59.
4. Hurst, K.R. et al. (2009) J. Virol. 83:7221.
5. Huang, C.Y. et al. (2009) Protein Sci. 18:2209.
6. Chan, K.H. et al. (2005) Clin Diagn Lab Immunol. 12:1317.
7. Mourez, T. et al. (2007) J. Virol Methods. 139:175.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.